Search Results
Dec 09, 2025, 23:19 ET Il Gruppo Menarini presenta i dati di fase 2 sulla combinazione di elacestrant (ORSERDU®) in pazienti affetti da carcinoma mammario metastatico (mBC) ER+, HER2- al Simposio sul cancro al seno di San Antonio del 2025
mBC ER+/HER2-, che presentano progressione della malattia durante la terapia endocrina (ET), con o senza precedente esposizione agli inibitori di CDK4/6. Questi risultati aggiornati mostrano inoltre che la sicurezza delle combinazioni è coerente con i profili di sicurezza noti di ciascuna terapia mirata
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 14:24 ET Menarini Group 於 2025 年聖安東尼奧乳癌研討會公佈 Elacestrant (ORSERDU®) 針對 ER+、HER2- 轉移性乳癌 (mBC) 患者的第 2 期聯合治療數據
醫學博士表示， 「Elacestrant 與 everolimus 或 abemaciclib 聯合使用的安全性特徵，與每種藥物已知的安全性特徵一致。並未發現新的安全訊號。」將於 SABCS 發表的 ELEVATE 數據顯示，對於曾在接受內分泌治療 (ET) 後病情惡化（不論是否曾使用 CDK4/6 抑制劑）的 ER+/HER2- mBC 患者，elacestrant 聯合 everolimus 或 abemaciclib 均顯示出一致的 PFS 效益，且不受 ESR1 突變狀態影響。最新結果亦顯示，聯合療法的安全性與各標靶療法加上標準護理內分泌療法的已知安全性一致。第
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 11:38 ET El Grupo Menarini presenta datos de la combinación de fase 2 de Elacestrant (ORSERDU®) en cáncer de mama
plus trastuzumab deruxtecan in patients with CDK4/6 inhibitor and endocrine-resistant HR+/HER2-low or HER2-ultralow metastatic breast cáncer (ERADICATE: Un estudio de fase Ib/II de elacestrant más trastuzumab deruxtecan en pacientes con inhibidor de CDK4/6 y cáncer de mama metastásico HR+/HER2-bajo
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 09:49 ET 메나리니 그룹, 2025 샌안토니오 유방암 심포지엄에서 엘라세스트란트(ORSERDU)®의 ER+, HER2- 전이성 유방암(mBC) 환자 대상 2상 병용 요법 데이터 발표
Endocrine Therapy (ET) + CDK4/6i)초록 번호: 1141발표 날짜 및 시간: 2025년 12월 10일 수요일 오후 12:30 – 2:00장소: Henry B. Convention Center발표 저자: 안토니오 요롬바르트-쿠삭((Antonio Llombart-Cussac))발표 제목: ERADICATE: CDK4/6 억제제 및 내분비 치료 내성이
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 15:17 ET Le groupe Menarini présente les données de la phase 2 sur l'association d'Elacestrant (ORSERDU®) chez des patientes atteintes d'un cancer du sein métastatique (mBC) ER+, HER2- lors du 2025 San Antonio Breast Cancer Symposium
patientes atteintes d'un CBM ER+/HER2-, dont la maladie progresse sous traitement endocrinien (TE), avec ou sans exposition préalable aux inhibiteurs de CDK4/6. Ces résultats actualisés montrent également que la sécurité des combinaisons est cohérente avec les profils de sécurité connus de chaque thérapie ciblée
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 14:47 ET Menarini Group präsentiert Daten zur Phase-2-Kombination von Elacestrant (ORSERDU®) bei Patientinnen mit ER+, HER2- metastasiertem Brustkrebs (mBC) auf dem San Antonio Breast Cancer Symposium 2025
Patientinnen mit ER+/HER2- mBC, die unter endokriner Therapie (ET) einen Krankheitsfortschritt erfahren, mit oder ohne vorherige Behandlung mit CDK4/6-Inhibitoren. Diese aktualisierten Ergebnisse zeigen auch, dass die Sicherheit der Kombinationen mit den bekannten Sicherheitsprofilen jeder zielgerichteten
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 13:41 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
ESR1 mutation status in patients with ER+/HER2- mBC, who experience disease progression on endocrine therapy (ET), with or without prior exposure to CDK4/6 inhibitors. These updated results also show that the safety of the combinations are consistent with the known safety profiles of each targeted therapy
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 13:30 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
ESR1 mutation status in patients with ER+/HER2- mBC, who experience disease progression on endocrine therapy (ET), with or without prior exposure to CDK4/6 inhibitors. These updated results also show that the safety of the combinations are consistent with the known safety profiles of each targeted therapy
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 04, 2025, 12:20 ET Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
second-line salvage therapy, with final analysis anticipated by year-end 2025 once 80 deaths are reached. The company's Phase 2 data for SLS009, a selective CDK9 inhibitor, in combination with azacitidine and venetoclax for relapsed or refractory AML have been accepted for presentation at the American Society
More news about: USA News Group
Dec 04, 2025, 08:30 ET Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium
Fire 3. December 10, 2025. 5:18-5:26 PM CSTSpotlight Posters Include: Personalized Acquired CDK4/6i Resistance: Associations with Baseline Characteristics Like Obesity in Real-World (RW) Clinical-Multiomics Data. #PD3-02Poster
More news about: Caris Life Sciences
Nov 28, 2025, 16:00 ET Immutable and Polygon Labs Announce Next Phase of Partnership: 5 Live Titles and Quest Rewards
this update shifts the focus squarely to discovery and rewards. The "Gaming on Polygon" hub remains the front door for Polygon PoS and Agglayer CDK-powered titles on Immutable Play, uniting ecosystems of games with shared quests, leaderboards, and a $100,000 community reward pool."This
More news about: Immutable
Nov 24, 2025, 16:30 ET Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
exploratory analysis of early changes in circulating tumor DNA (ctDNA) and correlation to clinical outcomes.Verzenio (abemaciclib; CDK4/6 inhibitor)In a poster presentation, Lilly will share results from a subgroup analysis of the Phase 3 monarchE trial, evaluating adjuvant
More news about: Eli Lilly and Company
Nov 20, 2025, 13:16 ET Accord BioPharma, Inc. Announces FDA Approval of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)
at high risk for severe hypocalcemia after denosumab products administration, which can lead to hospitalization, life-threatening events, or death. CDK-MBD and concomitant calcimimetic use further increase risk. Assess for mineral bone disorder before OSVYRTI treatment, monitor
More news about: Accord BioPharma
Nov 17, 2025, 08:05 ET Biotheryx Announces Completion of Enrollment in Phase 1a Clinical Trial of BTX-9341 for the Treatment HR+/HER2- Breast Cancer
oral degrader of CDK4/6, important targets for a range of cancers and clinically validated in HR+/HER2- breast cancer. In preclinical breast cancer models, BTX-9341 demonstrated superiority to CDK4/6 inhibitors through potent and highly selective catalytic degradation of CDK4 and CDK6, robust inhibition
More news about: Biotheryx, Inc.
Nov 12, 2025, 08:15 ET Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
DCIS and two in ER+/HER2- breast cancer. Further, monotherapy in DCIS and low risk cancer, and combination therapy in high-risk cancer, with Lilly's CDK4/6 inhibitor, Verzenio® (abemaciclib), are being investigated. Atossa's (Z)-endoxifen program is supported by a growing global intellectual property
More news about: Atossa Therapeutics Inc
Nov 05, 2025, 16:05 ET TrueCar Releases Third Quarter 2025 Financial Results
The excluded amount represents a gain on legal settlement resulting from the CDK Settlement Agreement.
More news about: TrueCar, Inc.
Oct 28, 2025, 08:11 ET Fosun Pharma Announces 2025Q3 Financial Results
self-developed Innovative Drugs from Fosun Pharma achieved key milestones in major markets. Notably, 1 additional indication for the innovative small molecule CDK4/6 inhibitor Fovinaciclib Citrate Capsules (Chinese trade name:复妥宁®), of which Fosun Pharma owns independent intellectual property rights, was approved
More news about: Fosun Pharma
Oct 28, 2025, 05:01 ET Group 1 Automotive Reports Third Quarter 2025 Financial Results
hurricanes and snow storms, and employment compensation costs associated with the cybersecurity incident experienced by third-party software provider, CDK Global LLC in June 2024. Because these non-core charges and gains materially affect the Company's financial condition or results in the specific period
More news about: Group 1 Automotive, Inc.
Oct 23, 2025, 08:33 ET BridGene Biosciences to Present Three Posters at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
BGP-1900 selectively bound PTPN2, offering a path toward targeted degradation strategies. In kinase assays, BGP-21172 showed strong selectivity for CDK7, and two ADK binders—BGP-1892 and BGP-13486—demonstrated nanomolar activity in target engagement assays. BridGene will present
More news about: BridGene Biosciences
Oct 23, 2025, 06:58 ET AutoNation Reports Third Quarter 2025 Results
business/property divestitures and asset impairments. Current periods also include cybersecurity insurance recoveries received in connection with the CDK outage.
More news about: AutoNation, Inc.
Oct 18, 2025, 10:42 ET Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
In the OptiTROP-Breast02 study, a total of 399 patients with HR+/HER2- BC who had progression on CDK4/6 inhibitors and received at least one prior line of chemotherapy in the advanced/metastatic setting were randomized (1:1) to receive sac-TMT or investigator's
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 17, 2025, 08:00 ET Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
program continue to differentiate Verzenio as a CDK4/6 inhibitor. In high-risk EBC, Verzenio has shown a persistent and deepening benefit beyond the two-year treatment period in the monarchE trial, an adjuvant study designed specifically to investigate a CDK4/6 inhibitor in a node-positive, high-risk EBC
More news about: Eli Lilly and Company
Oct 16, 2025, 08:00 ET Eilean Therapeutics Presents Novel, Selective, Brain-Permeable CDK2 Inhibitor for Treatment of CCNE1-Dependent Cancers
tolerability, and a broad therapeutic window in models of multiple cyclin-E1 (CCNE1)–CDK2–dependent neoplasms that exhibit poor response to current standard-of-care treatments, including approved CDK4/6 and investigational CDK2 inhibitors.
More news about: Eilean Therapeutics
Oct 14, 2025, 17:31 ET Anaplastic Astrocytoma Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight
eflornithine in the treatment of anaplastic glioma. Cothera Bioscience's Zotiraciclib is a potent oral CDK9 inhibitor capable of crossing the blood-brain barrier, where it downregulates short-lived, anti-apoptotic oncogene proteins such as Myc. It is being
More news about: DelveInsight Business Research, LLP
Oct 13, 2025, 06:45 ET Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
Presentation Highlights Verzenio (abemaciclib; CDK4/6 inhibitor): In a late-breaking oral presentation, Lilly will share results from the landmark seven-year analysis
More news about: Eli Lilly and Company